Integrated Filing — IndAS



General information about company
Scrip Code 524404
NSE Symbol MARKSANS
MSEI Symbol NOTLISTED
ISIN INE750C01026
Name of company MARKSANS PHARMA LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 19-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 08-May-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Pharmaceutical Formulation
Start date and time of board meeting 19-May-2025   18:30:00
End date and time of board meeting 19-May-2025   19:05:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2025-02-11
Indicate Company website link for updated RPT policy of the Company https://www.marksanspharma.com/codes-policies.html
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? Yes
No. of times funds raised during the quarter 1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
The Company has not defaulted on loans and debt securities.



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 2993570000 11743740000
Other income 78170000 698340000
Total income 3071740000 12442080000
2 Expenses
(a) Cost of materials consumed 1450600000 5371770000
(b) Purchases of stock-in-trade 167680000 1020610000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 23000000 6980000
(d) Employee benefit expense 288180000 1016780000
(e) Finance costs 3110000 11740000
(f) Depreciation, depletion and amortisation expense 81770000 294520000
(f) Other Expenses
1 Other Expenses 558370000 2287090000
Total other expenses 558370000 2287090000
Total expenses 2572710000 10009490000
3 Total profit before exceptional items and tax 499030000 2432590000
4 Exceptional items 0 0
5 Total profit before tax 499030000 2432590000
6 Tax expense
7 Current tax 115580000 521440000
8 Deferred tax 7540000 28430000
9 Total tax expenses 123120000 549870000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations 375910000 1882720000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period 375910000 1882720000
17 Other comprehensive income net of taxes -5130000 -3010000
18 Total Comprehensive Income for the period 370780000 1879710000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 453160000 453160000
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve 0
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 0.83 4.15
Diluted earnings (loss) per share from continuing operations 0.83 4.15
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 0.83 4.15
Diluted earnings (loss) per share from continuing and discontinued operations 0.83 4.15
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results
Textual Information(1) Current tax for the year include Current tax for earlier period Rs. 7.16 n n nThe audited standalone financial results for the year ended 31 March 2025 has been prepared on the basis of the standalone annual financial statements in accordance with the Indian Accounting Standards (Ind AS) as notified under the Companies (Indian Accounting Standards) Rules 2015 (as amended) specified under section 133 of the Companies Act, 2013 and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Regulation'), as amended were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meeting held on May 19, 2025. The Statutory Auditors of the Company have expressed an unmodified opinion on the audited standalone financial results for the year ended 31 March 2025. n nThe figures for the quarter ended 31 March 2025 and 31 March 2024 are the balancing figures between the audited figures in respect of full financial year and the unaudited published year-to-date figures upto 31 December for respective years which were subject to limited review. n nThe Company operates in one reportable business segment namely 'Pharmaceuticals' as per Ind AS 108 on n'Operating Segments'. n nThe Board of Directors in the meeting held on 19 May 2025 have recommended final dividend of 0.80 per equity nshare of 1 each 80 for the Financial Year 2024-25. n nThe above unaudited standalone financials results are available on the Company's website n(www.marksanspharma.com) and stock exchanges websites, BSE (www.bseindia.com) and NSE n(www.nseindia.com), where the shares of the Company are listed.



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities
Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 3535940000
Capital work-in-progress
Investment property
Goodwill 0
Other intangible assets 297770000
Intangible assets under development
Biological assets other than bearer plants
Investments accounted for using equity method
Non-current financial assets
Non-current investments 2657530000
Trade receivables, non-current
Loans, non-current 0
Other non-current financial assets 10840000
Total non-current financial assets 2668370000
Deferred tax assets (net) 11110000
Other non-current assets 217600000
Total non-current assets 6730790000
2 Current assets
Inventories 2052100000
Current financial asset
Current investments 7420000
Trade receivables, current 5495810000
Cash and cash equivalents 602680000
Bank balance other than cash and cash equivalents 2084230000
Loans, current 0
Other current financial assets 22910000
Total current financial assets 8213050000
Current tax assets (net)
Other current assets 557080000
Total current assets 10822230000
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 17553020000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 453160000
Other equity 13381700000
Total equity attributable to owners of parent 13834860000
Non controlling interest
Total equity 13834860000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other non-current financial liabilities 82580000
Total non-current financial liabilities 82580000
Provisions, non-current 57700000
Deferred tax liabilities (net) 121530000
Deferred government grants, Non-current
Other non-current liabilities
Total non-current liabilities 261810000
Current liabilities
Current financial liabilities
Borrowings, current 0
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 36330000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 1999010000
Total Trade payable 2035340000
Other current financial liabilities 217830000
Total current financial liabilities 2253170000
Other current liabilities 1083450000
Provisions, current 14470000
Current tax liabilities (Net) 105260000
Deferred government grants, Current 0
Total current liabilities 3456350000
3 Liabilities directly associated with assets in disposal group classified as held for sale 0
4 Regulatory deferral account credit balances and related deferred tax liability 0
Total liabilities 3718160000
Total equity and liabilites 17553020000
Disclosure of notes on assets and liabilities Textual Information(1)



Text Block
Textual Information(1) Other Current Financial Liabilities include Lease Liability - 25.84 nOther Intangible asset include Right of use asset Rs. 273.03 n n



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurements of the net defined benefit liabilities/assets -6860000 -4020000
Total Amount of items that will not be reclassified to profit and loss -6860000 -4020000
2 Income tax relating to items that will not be reclassified to profit or loss -1730000 -1010000
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss
5 Total Other comprehensive income -5130000 -3010000



Cash flow statement, indirect
Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2024
B Date of end of reporting period 31-Mar-2025
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 2432590000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 11740000
Adjustments for decrease (increase) in inventories -143610000
Adjustments for decrease (increase) in trade receivables, current -1826860000
Adjustments for decrease (increase) in trade receivables, non-current 0
Adjustments for decrease (increase) in other current assets -143520000
Adjustments for decrease (increase) in other non-current assets -710000
Adjustments for other financial assets, non-current -6510000
Adjustments for other financial assets, current 1020000
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current 440870000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities 67170000
Adjustments for increase (decrease) in other non-current liabilities 0
Adjustments for depreciation and amortisation expense 294520000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current -9100000
Adjustments for provisions, non-current 13040000
Adjustments for other financial liabilities, current 27070000
Adjustments for other financial liabilities, non-current 0
Adjustments for unrealised foreign exchange losses gains -48770000
Adjustments for dividend income 263690000
Adjustments for interest income 182160000
Adjustments for share-based payments 0
Adjustments for fair value losses (gains) 40060000
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow -6610000
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items 79040000
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) -1657010000
Net cash flows from (used in) operations 775580000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 465400000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities 310180000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 1010000
Purchase of property, plant and equipment 1199100000
Proceeds from sales of investment property 0
Purchase of investment property 0
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 263690000
Interest received 218160000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 888640000
Net cash flows from (used in) investing activities 172400000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 0
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 0
Repayments of borrowings 0
Payments of lease liabilities 27290000
Dividends paid 271900000
Interest paid 0
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) financing activities -299190000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 183390000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents 183390000
Cash and cash equivalents cash flow statement at beginning of period 419290000
Cash and cash equivalents cash flow statement at end of period 602680000





Details of Impact of Audit Qualification
Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 M S K A & Associates Yes 31-Jul-2027


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)
Mode of Fund Raising Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 18-Jan-2023
Amount Raised 3.723999976E+15
Report filed for Quarter ended 31-Mar-2025
Monitoring Agency Not Applicable
Monitoring Agency Name, if applicable
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation false
Comments of the Audit Committee after review false
Comments of the auditors, if any false
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 The proceeds of the preferential issue are proposed to be used to strengthen the capital base and to enhance long term financial resources of the Company in order to fund expansion program of the Company. None 3.723999976E+15 0 3.373801653E+15 0 No Deviations. Further please note that the funds are not raised during this quarter, and the reporting of the Statement of Deviation and Variation is being made for the funds raised in prior periods as mentioned.


Signatory Details
Name of signatory Harshavardhan Panigrahi
Designation of person Company Secretary and Compliance Officer
Place Mumbai
Date 28-May-2025




Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Marksans Pharma Limited Nova Pharmaceuticals Australasia Pty Ltd Subsidiary Sale of goods or services 0 172450000 0 0
2 Marksans Pharma Limited Bell, Sons and Co. (Druggists) Limited Step down Subsidiary Sale of goods or services 0 564220000 0 0
3 Marksans Pharma Limited Bell, Sons and Co. (Druggists) Limited Step down Subsidiary Any other transaction GURANTEE COMMISSION 0 331110000 0 0
4 Marksans Pharma Limited Bell, Sons and Co. (Druggists) Limited Step down Subsidiary Purchase of goods or services 0 1910000 0 0
5 Marksans Pharma Limited Relonchem Limited Step down Subsidiary Sale of goods or services 0 874350000 0 0
6 Marksans Pharma Limited Relonchem Limited Step down Subsidiary Any other transaction REIMBURSEMENT OF EXPENSES 0 5940000 0 0
7 Marksans Pharma Limited Time-Cap Laboratories Inc Step down Subsidiary Sale of goods or services 0 3874870000 0 0
8 Marksans Pharma Limited Time-Cap Laboratories Inc Step down Subsidiary Sale of fixed assets 0 420000 0 0
9 Marksans Pharma Limited Time-Cap Laboratories Inc Step down Subsidiary Any other transaction GURANTEE COMMISSION 0 598290000 0 0
10 Marksans Pharma Limited Time-Cap Laboratories Inc Step down Subsidiary Any other transaction RECEIVABLE 0 4333050000 0 0
11 Marksans Pharma Limited Time-Cap Laboratories Inc Step down Subsidiary Purchase of fixed assets 00 510000 0 0
12 Marksans Pharma Limited Time-Cap Laboratories Inc Step down Subsidiary Purchase of goods or services 0 16120000 0 0
13 Marksans Pharma Limited Time-Cap Laboratories Inc Step down Subsidiary Any other transaction PAYABLE 0 14010000 0 0
14 Marksans Pharma Limited Bell, Sons and Co. (Druggists) Limited Step down Subsidiary Any other transaction RECEIVABLE 0 229110000 0 0
15 Marksans Pharma Limited Relonchem Limited Step down Subsidiary Any other transaction GURANTEE COMMISSION 0 171070000 0 0
16 Marksans Pharma Limited Relonchem Limited Step down Subsidiary Any other transaction RECEIVABLE 0 957050000 0 0
17 Marksans Pharma Limited Modern Access Health Care Step down Subsidiary Sale of goods or services 0 2080000 0 0
18 Marksans Pharma Limited Mark Saldanha Promoter & Key Managerial Personnel Remuneration 0 30620000 0 0
19 Marksans Pharma Limited Sandra Saldanha Promoter & Key Managerial Personnel Remuneration 00 3540000 0 0
20 Marksans Pharma Limited Jitendra Sharma Key Managerial Personnel Remuneration 0 8310000 0 0
21 Marksans Pharma Limited Harshavardhan Panigrahi Key Managerial Personnel Remuneration 0 1510000 0 0
22 Marksans Pharma Limited Varddhman Jain Key Managerial Personnel Remuneration 0 10560000 0 0
23 Marksans Pharma Limited Mark Saldanha Promoter & Key Managerial Personnel Remuneration 0 5330000 0 0
24 Marksans Pharma Limited Abhinna Sundar Mohanty Non-Executive - Independent Director Any other transaction Director Sitting fees 0 10000 0 0
25 Marksans Pharma Limited Buddharaju Seetharama Raju Non-Executive - Independent Director Any other transaction Director Sitting fees 0 20000 0 0
26 Marksans Pharma Limited Digant Mahesh Parikh Non-Executive - Independent Director Any other transaction Director Sitting fees 0 300000 0 0
27 Marksans Pharma Limited Shailaja Vardan Non-Executive - Independent Director Any other transaction Director Sitting fees 0 200000 0 0
28 Marksans Pharma Limited Nova Pharmaceuticals Australasia Pty Ltd Subsidiary Any other transaction RECEIVABLE 0 425420000 0 0
Total value of transaction during the reporting period 12632380000